Siemens Healthineers to Acquire Novartis' Molecular Imaging Business in $224 Million Deal

Aug 26, 2024, 12:36 PM

Siemens Healthineers has agreed to acquire a part of Novartis' business specializing in radioactive chemicals used for cancer scans. The $224 million deal involves the molecular imaging business for Fluorine-18 positron emission tomography (PET) scans. This acquisition is expected to further boost Siemens Healthineers' healthcare operations. Novartis confirmed receiving a binding offer from Siemens Healthineers for this acquisition.